Who We Are
Sagent Pharmaceuticals, Inc., a wholly owned subsidiary of Nichi-Iko Pharmaceuticals Co. Ltd, is a customer-focused specialty pharmaceutical company that provides an extensive portfolio of injectable products and fulfills the evolving needs of the patients it serves through its unique network of global resources.
- Provides specialty injectable products across multiple therapeutic areas, including anti-infectives, critical care, oncology, and urology; and offers multiple packaging options, from premix bags and prefilled syringes to single-dose vials and pharmacy bulk package vials
- Expands its current product offering to include quality, cost-efficient biosimilars
- Develops and produces products in state-of-the-art manufacturing facilities that extend across a wide range of therapeutic categories
- Delivers products in a timely manner, ensuring consistency of supply, quality, and service
Most importantly, Sagent strives to reduce medication errors and improve patient safety by designing enhanced product labels and packaging that feature easy-to-read product names, dosage strengths, and bar codes.
To learn more, visit us at www.sagentpharma.com.
Sagent and Biosimilars
With a distinct focus on patients and safety, and as a leader in generic injectable products, Sagent is well positioned to enter the biosimilar market, with an eye for improving care in a potentially cost-efficient manner.
Our phase III RADIANCE (NCT02990806) clinical trial is underway to demonstrate that Sagent’s infliximab biosimilar is interchangeable with the United States–licensed Remicade®1 (infliximab) in patients with rheumatoid arthritis not adequately responding to methotrexate.2 Sagent hopes to introduce the first interchangeable biosimilar into the United States market in the near future.
Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc; 2017.
ClinicalTrials.gov. A phase 3 study of NI-071 in patients with rheumatoid arthritis (RADIANCE). https://clinicaltrials.gov/ct2/show/NCT02990806. Updated March 22, 2018. Accessed May 14, 2018.